Phase 3 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Written agreement to take part in the trial has been provided by the person or their legal representative before any screening begins.
• The person has a specific type of prostate cancer called acinar adenocarcinoma (including cases where the cancer cells have changed in a particular way called neuro-endocrine dedifferentiation).
• The cancer is "oligoprogressive," meaning only a small number of areas (up to 3 spots outside the brain) are growing or newly appeared on scans taken within 6 weeks before joining the trial (confirm with trial site for full imaging details).
• The person falls into one of two groups: either their prostate cancer is being managed with ongoing hormone therapy alone (Type 1), or with hormone therapy plus an additional drug or past chemotherapy with docetaxel (Type 2).
• The cancer is no longer responding to hormone therapy, shown by a very low testosterone level in the blood (below 50 ng/dL).
• The original prostate tumor was previously treated with radiotherapy or surgery — or that treatment will be given as part of the trial if it has not yet been done.
• The person has a general health and activity level rated as 0, 1, or 2 on the WHO performance scale (meaning they are able to carry out at least some daily activities).
• The person is 18 years of age or older.
• There are no major psychological, social, or location-related factors that would make it difficult to follow the trial's requirements.
• The person's case has been reviewed and approved by a specialist multidisciplinary medical team.

Who may not be able to join:

• People with a different type of prostate cancer called ductal adenocarcinoma or small-cell prostate cancer.
• People whose testosterone level is above 50 ng/mL in the blood.
• People whose cancer is "poly-progressive," meaning more than 3 areas are growing or spreading on scans.
• People who have another active cancer (other than prostate cancer) that could affect how trial results are interpreted.
• People whose previous cancer treatments or other health conditions mean that a type of targeted radiation treatment called SBRT cannot safely be given.
• People with a spinal bone lesion that is causing significant pain, threatening nerve function, or at high risk of breaking.
• People who have previously been treated with radionuclide therapy, cabazitaxel, or PARP-inhibitor drugs.
• People whose cancer was growing while they were receiving docetaxel chemotherapy.
• People who are not able to understand the trial procedures or provide signed consent.

Important: Always verify eligibility with the trial site directly before applying.